Director R. Keith Woods not standing for re-election to Rocket board

ROCKET PHARMACEUTICALS, INC.

R. Keith Woods informed board he accepted COO role at another biopharma company; will not stand for re-election at 2025 annual meeting.
His term as director and membership on audit and commercial committees ends at the 2025 annual meeting.
Departure is not due to any disagreement with Rocket's operations, policies, or practices.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

R. Keith Woods

Director

RCKT · ROCKET PHARMACEUTICALS, INC.

Filed: April 29, 2025, 7:59 PM ET

On April 26, 2025, R. Keith Woods informed the board of directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”) that he has accepted a Chief Operating Officer position with a biopharmaceutical company and therefore has decided not to stand for re-election to the Board at the Company’s upcoming 2025 annual meeting (the “2025 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

R. Keith Woods departed as Director at ROCKET PHARMACEUTICALS, INC..

Action: decided not to stand for re-election
Role: Director

Exact text from the filing

On April 26, 2025, R. Keith Woods informed the board of directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”) that he has accepted a Chief Operating Officer position with a biopharmaceutical company and therefore has decided not to stand for re-election to the Board at the Company’s upcoming 2025 annual meeting (the “2025 Annual Meeting”).

View on SEC.gov

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-25-016338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.